setrusumab
Monoclonal antibody
Evidence outlook · lead readout
Cosmic (NCT05768854) · Osteogenesis Imperfecta
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found. A further registrational readout is expected around 2027-01.
Cosmic (NCT05768854): The trial was randomized and used an active comparator (bisphosphonate) rather than placebo, with a genuine hard clinical endpoint (fracture rate), but it was open-label with no blinding and enrolled only 69 children. The primary comparison showed a numerical advantage for setrusumab that did not reach statistical significance, so despite reasonable design elements this is evidence of an unclear/negative effect rather than a proven benefit.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Cosmic NCT05768854 · Osteogenesis Imperfecta The trial was randomized and used an active comparator (bisphosphonate) rather than placebo, with a genuine hard clinical endpoint (fracture rate), but it was open-label with no blinding and enrolled only 69 children. The primary comparison showed a numerical advantage for setrusumab that did not reach statistical significance, so despite reasonable design elements this is evidence of an unclear/negative effect rather than a proven benefit. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05768854 | 3 | Annualized Rate of All Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures, at the Primary Analysis (Up to 24 Months) 2025-10-23 | COSMIC (NCT05768854), primary endpoint annualized clinical fracture rate: setrusumab showed a numerical reduction vs bisphosphonate that did not meet statistical significance | Partial signal | link ↗ |
View 1 more trial
Orbit NCT05125809 · Osteogenesis Imperfecta Registry: NCT05125809 | 2/3 | Phase 2: Percent Change in Serum Amino-terminal Propeptide of Type 1 Procollagen (P1NP) from Baseline at Month 1 (Baseline, Month 1); Phase 3: Annualized Rate of All Radiographically-Confirmed Fractures, Excluding Morphometric Vertebral Fractures and Fractures of the Fingers, Toes, Face, and Skull at the Primary Analysis (Up to Month 24) 2025-10-20 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow setrusumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
January 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent